Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Amer M Zeidan; Pierre Fenaux; Marco Gobbi; Jiří Mayer; Gail J Roboz; Jürgen Krauter; Tadeusz Robak; Hagop M Kantarjian; Jan Novák; Wieslaw W Jedrzejczak; Xavier Thomas; Mario Ojeda-Uribe; Yasushi Miyazaki; Yoo Hong Min; Su-Peng Yeh; Joseph M Brandwein; Liana Gercheva; Judit Demeter; Elizabeth A Griffiths; Karen W L Yee; Jean-Pierre J Issa; Jan Philipp Bewersdorf; Harold Keer; Yong Hao; Mohammad Azab; Hartmut Döhner

doi:10.1182/blood.2022015832

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Blood. 2022 Jul 21;140(3):285-289. doi: 10.1182/blood.2022015832.

Authors

Amer M Zeidan^{1

2}, Pierre Fenaux³, Marco Gobbi⁴, Jiří Mayer⁵, Gail J Roboz^{6

7}, Jürgen Krauter⁸, Tadeusz Robak⁹, Hagop M Kantarjian¹⁰, Jan Novák¹¹, Wieslaw W Jedrzejczak¹², Xavier Thomas¹³, Mario Ojeda-Uribe¹⁴, Yasushi Miyazaki¹⁵, Yoo Hong Min¹⁶, Su-Peng Yeh¹⁷, Joseph M Brandwein¹⁸, Liana Gercheva¹⁹, Judit Demeter²⁰, Elizabeth A Griffiths²¹, Karen W L Yee²², Jean-Pierre J Issa²³, Jan Philipp Bewersdorf^{1

2

24}, Harold Keer²⁵, Yong Hao²⁵, Mohammad Azab²⁵, Hartmut Döhner²⁶

Affiliations

¹ Section of Hematology, Department of Medicine, Yale University, New Haven, CT.
² Yale Cancer Center, New Haven, CT.
³ Hôpital Saint Louis, Paris, France.
⁴ Ospedale Policlinico San Martino, Genova, Italy.
⁵ Fakultní Nemocnice, Brno, Czech Republic.
⁶ Division of Hematology and Medical Oncology, Weill Cornell Medicine, Cornell University, New York, NY.
⁷ NewYork-Presbyterian Hospital, New York, NY.
⁸ Städtisches Klinikum Braunschweig, Braunschweig, Germany.
⁹ Copernicus Memorial Hospital, Lodz, Poland; Department of Hematology, Medical University of Lodz, Lodz, Poland.
¹⁰ MD Anderson Cancer Center, University of Texas, Houston, TX.
¹¹ Fakultní Nemocnice Královské Vinohrady, Praha, Czech Republic.
¹² Uniwersyteckie Centrum Kliniczne, Warszawskiego Uniwersytetu Medycznego, Warsaw, Poland.
¹³ Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
¹⁴ Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Mulhouse, France.
¹⁵ Nagasaki University Hospital, Nagasaki, Japan.
¹⁶ Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
¹⁷ China Medical University Hospital, Taichung, Taiwan, Republic of China.
¹⁸ University of Alberta Hospital, Edmonton, Canada.
¹⁹ Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria.
²⁰ Semmelweis Egyetem, Budapest, Hungary.
²¹ Roswell Park Cancer Institute, Buffalo, NY.
²² Princess Margaret Cancer Centre, Toronto, Canada.
²³ Coriell Institute for Medical Research, Camden, NJ.
²⁴ Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
²⁵ Astex Pharmaceuticals, Inc., Pleasanton, CA; and.
²⁶ Ulm University Hospital, Ulm, Germany.

No abstract available

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Azacitidine* / therapeutic use
Decitabine / adverse effects
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / etiology
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Decitabine
Azacitidine

MeSH terms

Substances

Grants and funding